SHORT MINI-FUTURE - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 04:23:12 2024-05-22 am EDT | ||
| 4.51 EUR | 0.00% |
|
| Current month | +2.97% | ||
| 1 month | +13.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 4.51 | 0.00% |
| 24-05-21 | 4.51 | +2.73% |
| 24-05-20 | 4.39 | +0.92% |
| 24-05-17 | 4.35 | +0.23% |
| 24-05-16 | 4.34 | +0.93% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 04:23 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VX9ZZ1 |
| ISIN | DE000VX9ZZ12 |
| Date issued | 2022-04-11 |
| Strike | 91.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.62 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.51 € |
|---|---|
| Lowest since issue | 1.13 € |
| Spread | 0.02 € |
| Spread % | 0.44% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
42.27
USD
Average target price
53.19
USD
Spread / Average Target
+25.84%
- Stock Market
- Certificates
- Certificat